Anxiolytics

Chapter

Abstract

Anxiety is a frequent comorbid illness with neurological disorders. This chapter looks at the most common anxiolytics currently used and gives guidance in their proper use. The mainstays of long-term treatment in any of the anxiety disorders are the selective serotonin reuptake inhibitors (SSRIs) and serotonin/norepinephrine reuptake inhibitors (SNRIs). Acute treatment relies on benzodiazepines. Despite the effectiveness of the SSRIs and SNRIs, other medications are commonly used. Patient features which are prominent in the decision on which agent to use and patient features most commonly experienced in clinical practice are discussed. The nuances and rationales for various medications are reviewed. Additionally, the use of adjunctive medications is examined.

Keywords

Anxiolytics Neurological conditions Generalized anxiety disorder Panic disorder SSRIs SNRIs 

References

  1. 1.
    Kessler RC, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–84.CrossRefGoogle Scholar
  2. 2.
    Cassidy K-L, Rector NA. The silent geriatric giant: anxiety disorders in late life. Geriatr Aging. 2008;11(3):150–6.Google Scholar
  3. 3.
    Mahableshwarkar AR, et al. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract. 2014;68(1):49–59.CrossRefGoogle Scholar
  4. 4.
    Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72–90.CrossRefGoogle Scholar
  5. 5.
    Lambiase MJ, Kubzansky LD, Thurston RC. Prospective study of anxiety and incident stroke. Stroke. 2014;45(2):438–43.CrossRefGoogle Scholar
  6. 6.
    Tully PJ, Cosh SM, Baune BT. A review of the affects of worry and generalized anxiety disorder upon cardiovascular health and coronary heart disease. Psychol Health Med. 2013;18(6):627–44.CrossRefGoogle Scholar
  7. 7.
    Wands K, et al. A questionnaire investigation of anxiety and depression in early dementia. J Am Geriatr Soc. 1990;38(5):535–8.CrossRefGoogle Scholar
  8. 8.
    Rosenberg PB, et al. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(7):685–95.CrossRefGoogle Scholar
  9. 9.
    Diprose W, Sundram F, Menkes DB. Psychiatric comorbidity in psychogenic nonepileptic seizures compared with epilepsy. Epilepsy Behav. 2016;56:123–30.CrossRefGoogle Scholar
  10. 10.
    Boeschoten RE, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;372:331–41.CrossRefGoogle Scholar
  11. 11.
    Seo JG, Park SP. Validation of the generalized anxiety disorder-7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain. 2015;16:97.CrossRefGoogle Scholar
  12. 12.
    Ayerbe L, et al. Natural history, predictors and associated outcomes of anxiety up to 10 years after stroke: the South London Stroke Register. Age Ageing. 2014;43(4):542–7.CrossRefGoogle Scholar
  13. 13.
    Isais-Millan S, et al. Prevalence of neuropsychiatric disorders in drug-naive subjects with Parkinson’s disease (PD). Gac Med Mex. 2016;152(3):357–63.PubMedGoogle Scholar
  14. 14.
    Zhao QF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.CrossRefGoogle Scholar
  15. 15.
    Bandyopadhyay TK, et al. Neuropsychiatric profiles in patients with Alzheimer’s disease and vascular dementia. Ann Indian Acad Neurol. 2014;17(3):325–30.CrossRefGoogle Scholar
  16. 16.
    Prediger RD, et al. Anxiety in Parkinson’s disease: a critical review of experimental and clinical studies. Neuropharmacology. 2012;62(1):115–24.CrossRefGoogle Scholar
  17. 17.
    Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–12.CrossRefGoogle Scholar
  18. 18.
    Dissanayaka NN, et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord. 2010;25(7):838–45.CrossRefGoogle Scholar
  19. 19.
    Shiba M, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord. 2000;15(4):669–77.CrossRefGoogle Scholar
  20. 20.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.Google Scholar
  21. 21.
    Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2011;14(5):697–710.CrossRefGoogle Scholar
  22. 22.
    Leentjens AF, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2015–25.CrossRefGoogle Scholar
  23. 23.
    Allgulander C. Generalized anxiety disorder: a review of recent findings. J Exp Clin Med. 2012;4(2):88–91.CrossRefGoogle Scholar
  24. 24.
    Spitzer RL, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.CrossRefGoogle Scholar
  25. 25.
    Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res. 2011;63(S11):S467–72.CrossRefGoogle Scholar
  26. 26.
    Zung WW. A rating instrument for anxiety disorders. Psychosom J Consult Liaison Psychiatry. 1971;12:371–9.Google Scholar
  27. 27.
    Pachana NA, et al. Development and validation of the geriatric anxiety inventory. Int Psychogeriatr. 2007;19(1):103–14.CrossRefGoogle Scholar
  28. 28.
    Matheson SF, et al. Validity and reliability of the geriatric anxiety inventory in Parkinson’s disease. Australas J Ageing. 2012;31(1):13–6.CrossRefGoogle Scholar
  29. 29.
    Katzman MA, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.CrossRefGoogle Scholar
  30. 30.
    Buoli M, et al. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother. 2013;14(2):175–84.CrossRefGoogle Scholar
  31. 31.
    Jiang HY, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13(1):42–50.e3.CrossRefGoogle Scholar
  32. 32.
    Pollack M, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65(5):551–62.CrossRefGoogle Scholar
  33. 33.
    Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013;28(1):33–45.CrossRefGoogle Scholar
  34. 34.
    Rector TS, et al. Outcomes of citalopram dosage risk mitigation in a veteran population. Am J Psychiatry. 2016;173(9):896–902.CrossRefGoogle Scholar
  35. 35.
    Rudroju N, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16(6):E705–14.PubMedGoogle Scholar
  36. 36.
    Rafael CF, et al. Current pharmacological interventions in panic disorder. CNS Neurol Disord Drug Targets. 2014;13(6):1057–65.CrossRefGoogle Scholar
  37. 37.
    Gommoll C, et al. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. Int Clin Psychopharmacol. 2015;30(6):297–306.CrossRefGoogle Scholar
  38. 38.
    Pae CU, et al. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res. 2015;64:88–98.CrossRefGoogle Scholar
  39. 39.
    Baldwin DS, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39.CrossRefGoogle Scholar
  40. 40.
    Montgomery S, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008;193(5):389.CrossRefGoogle Scholar
  41. 41.
    Stein DJ, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26(8):614–28.CrossRefGoogle Scholar
  42. 42.
    Mezhebovsky I, et al. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry. 2013;28(6):615–25.CrossRefGoogle Scholar
  43. 43.
    Albert U, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016;31(5):249–58.CrossRefGoogle Scholar
  44. 44.
    Freire RC, et al. Treatment-resistant panic disorder: a systematic review. Expert Opin Pharmacother. 2016;17(2):159–68.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Departments of Psychiatry and Behavioral Neuroscience and Internal MedicineSaint Louis University School of MedicineSt. LouisUSA
  2. 2.Maryville UniversitySt. LouisUSA

Personalised recommendations